UK relaunches West Nile virus surveillance:
This article was originally published in Clinica
Executive Summary
The UK's Health Protection Agency has launched its latest annual West Nile virus enhanced surveillance programme. The programme involves testing for WNV in blood and cerebrospinal fluid samples, taken from all patients with encephalitis or viral meningitis with no known cause. The HPA has requested that clinicians and laboratories refer relevant samples to the HPA's central laboratory in Porton Down. The scheme, which is in its fourth year, operates during the UK's summer months, when there is WNV activity in other countries, and is designed to screen those returning from countries where WNV has an impact, such as Africa, west and central Asia, Europe, the Middle East and North America.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.